PMID- 30052716
OWN - NLM
STAT- MEDLINE
DCOM- 20190520
LR  - 20220408
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 150
IP  - 5
DP  - 2018 Oct 1
TI  - The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms: 
      An ACLPS Critical Review.
PG  - 375-384
LID - 10.1093/ajcp/aqy076 [doi]
AB  - OBJECTIVES: Chromosome (G-banding) and fluorescence in situ hybridization (FISH) 
      serve as the primary methodologies utilized for detecting genetic aberrations in 
      hematologic neoplasms. Chromosomal microarray can detect copy number aberrations 
      (CNAs) with greater resolution when compared to G-banding and FISH, and can also 
      identify copy-neutral loss of heterozygosity (CN-LOH). The purpose of our review 
      is to highlight a preselected group of hematologic neoplasms for which 
      chromosomal microarray has the greatest clinical utility. METHODS: A case-based 
      approach and review of the literature was performed to identify the advantages 
      and disadvantages of utilizing chromosomal microarray for specific hematologic 
      neoplasms. RESULTS: Chromosomal microarray identified CNAs and CN-LOH of clinical 
      significance, and could be performed on fresh or paraffin-embedded tissue and 
      liquid neoplasms. Microarray studies could not detect balanced rearrangements, 
      low-level clones, or distinguish independent clones. CONCLUSIONS: When utilized 
      appropriately, chromosomal microarray can provide clinically significant 
      information that complements traditional cytogenetic testing methodologies.
FAU - Peterson, Jess F
AU  - Peterson JF
AD  - Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics 
      and Genomics, Mayo Clinic, Rochester, MN.
FAU - Van Dyke, Daniel L
AU  - Van Dyke DL
AD  - Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics 
      and Genomics, Mayo Clinic, Rochester, MN.
FAU - Hoppman, Nicole L
AU  - Hoppman NL
AD  - Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics 
      and Genomics, Mayo Clinic, Rochester, MN.
FAU - Kearney, Hutton M
AU  - Kearney HM
AD  - Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics 
      and Genomics, Mayo Clinic, Rochester, MN.
FAU - Sukov, William R
AU  - Sukov WR
AD  - Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics 
      and Genomics, Mayo Clinic, Rochester, MN.
FAU - Greipp, Patricia T
AU  - Greipp PT
AD  - Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics 
      and Genomics, Mayo Clinic, Rochester, MN.
FAU - Ketterling, Rhett P
AU  - Ketterling RP
AD  - Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics 
      and Genomics, Mayo Clinic, Rochester, MN.
FAU - Baughn, Linda B
AU  - Baughn LB
AD  - Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics 
      and Genomics, Mayo Clinic, Rochester, MN.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
SB  - IM
MH  - Adolescent
MH  - Burkitt Lymphoma/*diagnosis/genetics
MH  - *Chromosome Aberrations
MH  - Chromosome Banding
MH  - Comparative Genomic Hybridization
MH  - Female
MH  - Hematologic Neoplasms/*diagnosis/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotype
MH  - Leukemia, B-Cell/*diagnosis/genetics
MH  - Loss of Heterozygosity/genetics
MH  - Male
MH  - Middle Aged
MH  - Oligonucleotide Array Sequence Analysis/*methods
MH  - Polymorphism, Single Nucleotide/genetics
EDAT- 2018/07/28 06:00
MHDA- 2019/05/21 06:00
CRDT- 2018/07/28 06:00
PHST- 2018/07/28 06:00 [pubmed]
PHST- 2019/05/21 06:00 [medline]
PHST- 2018/07/28 06:00 [entrez]
AID - 5056501 [pii]
AID - 10.1093/ajcp/aqy076 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2018 Oct 1;150(5):375-384. doi: 10.1093/ajcp/aqy076.